Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,038
  • Shares Outstanding, K 620
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,860 K
  • EBIT $ -13 M
  • EBITDA $ -13 M
  • 60-Month Beta 2.62
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +333,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.11 +6.55%
on 12/03/25
8.10 -19.63%
on 12/10/25
-0.22 (-3.27%)
since 11/19/25
3-Month
6.04 +7.78%
on 11/14/25
10.59 -38.52%
on 10/08/25
-1.47 (-18.42%)
since 09/19/25
52-Week
4.93 +32.05%
on 08/15/25
114.00 -94.29%
on 02/14/25
-59.49 (-90.14%)
since 12/19/24

Most Recent Stories

More News
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints Rami Levin as President and CEO

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for primary and metastatic cancers of the brain and central nervous system, reported a leadership transition under...

CNSP : 6.51 (-2.54%)
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Talks Bold Strategy to Treat GBM in BioMedWire Podcast

CNS Pharmaceuticals (NASDAQ: CNSP) was featured in a BioMedWire Podcast discussing its sharpened focus on glioblastoma multiforme (“GBM”), one of the deadliest and least treatable forms of cancer....

CNSP : 6.51 (-2.54%)
CNS Pharmaceuticals (NASDAQ: CNSP) Reports Q3 Results and Advances Lead Candidate TPI 287 Toward Phase 2 GBM Study

CNS Pharmaceuticals (NASDAQ: CNSP) reported third-quarter 2025 results and highlighted continued progress with TPI 287, its blood-brain barrier–permeable abeotaxane in development for glioblastoma and...

CNSP : 6.51 (-2.54%)
CNS Pharmaceuticals (NASDAQ: CNSP) Targets Glioblastoma with Innovative Therapies, Addressing One of Oncology’s Greatest Unmet Needs

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in novel treatments for primary and metastatic brain cancers is sharpening its focus on glioblastoma multiforme (“GBM”),...

CNSP : 6.51 (-2.54%)
BMWYY : 29.2000 (+4.58%)
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Discusses Drug Development and Market Potential on BioMedWire Podcast

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in novel treatments for primary and metastatic brain cancers, was featured in the latest episode of The BioMedWire Podcast hosted...

CNSP : 6.51 (-2.54%)
CNS Pharmaceuticals (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for cancers in the brain and central nervous system, reported a Q2 2025 net loss of $2.4 million, slightly improved...

CNSP : 6.51 (-2.54%)
JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025

Register for the three-day event here

AKTX : 0.2601 (+6.16%)
NUWE : 2.16 (unch)
AIM : 1.4200 (+4.36%)
AMIX : 0.6250 (-0.92%)
SNTI : 1.2000 (+2.56%)
CNSP : 6.51 (-2.54%)
NVNO : 0.3200 (-7.75%)
MBRX : 3.90 (+1.83%)
GRI : 0.3400 (-8.03%)
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Featured in Virtual Investor Summer Spotlight Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for cancers of the brain and central nervous system, announced that CEO John Climaco participated in the Virtual Investor...

CNSP : 6.51 (-2.54%)
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

- Video webcasts from participating companies now available here

AKTX : 0.2601 (+6.16%)
NUWE : 2.16 (unch)
OTLK : 2.01 (-2.90%)
AMIX : 0.6250 (-0.92%)
SNTI : 1.2000 (+2.56%)
CNSP : 6.51 (-2.54%)
PALI : 1.8300 (+9.58%)
NVNO : 0.3200 (-7.75%)
GRI : 0.3400 (-8.03%)
MBRX : 3.90 (+1.83%)
CNS Pharmaceuticals (NASDAQ: CNSP) Announces 1-for-12 Reverse Stock Split Effective July 22

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company focused on treating brain and CNS cancers, will implement a 1-for-12 reverse stock split effective July 22, 2025. Its common stock will continue...

CNSP : 6.51 (-2.54%)

Business Summary

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is...

See More

Key Turning Points

3rd Resistance Point 7.28
2nd Resistance Point 7.12
1st Resistance Point 6.82
Last Price 6.51
1st Support Level 6.36
2nd Support Level 6.20
3rd Support Level 5.90

See More

52-Week High 114.00
Fibonacci 61.8% 72.34
Fibonacci 50% 59.47
Fibonacci 38.2% 46.59
Last Price 6.51
52-Week Low 4.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar